5 Stocks Underperforming Today In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 20 points (0.1%) at 14,984 as of Friday, Aug. 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,794 issues advancing vs. 1,149 declining with 104 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Chemocentryx ( CCXI), down 33.8%, and Allergan ( AGN), down 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Shire ( SHPG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $0.66 (-0.6%) to $113.32 on heavy volume. Thus far, 293,022 shares of Shire exchanged hands as compared to its average daily volume of 349,100 shares. The stock has ranged in price between $112.88-$113.54 after having opened the day at $113.30 as compared to the previous trading day's close of $113.99.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $21.4 billion and is part of the health care sector. Shares are up 23.7% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Biomarin Pharmaceutical ( BMRN) is down $0.79 (-1.2%) to $64.46 on light volume. Thus far, 174,037 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $64.14-$65.49 after having opened the day at $65.47 as compared to the previous trading day's close of $65.25.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $9.0 billion and is part of the health care sector. Shares are up 32.6% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $0.88 (-1.1%) to $77.52 on light volume. Thus far, 329,388 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $77.47-$79.00 after having opened the day at $78.40 as compared to the previous trading day's close of $78.40.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.8 billion and is part of the health care sector. Shares are up 87.1% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Actavis ( ACT) is down $1.16 (-0.9%) to $133.54 on light volume. Thus far, 378,018 shares of Actavis exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $132.88-$135.30 after having opened the day at $135.17 as compared to the previous trading day's close of $134.70.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $17.8 billion and is part of the health care sector. Shares are up 56.4% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $1.42 (-1.3%) to $105.35 on light volume. Thus far, 485,624 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $104.84-$107.00 after having opened the day at $107.00 as compared to the previous trading day's close of $106.77.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $20.6 billion and is part of the health care sector. Shares are up 12.4% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries